Ambroxol Hydrochloride

證據等級: L5

預測適應症: 0 個

Ambroxol Hydrochloride: Mucolytic Agent — TxGNN Prediction Pending

One-Sentence Summary

Ambroxol Hydrochloride is a well-established mucolytic and expectorant agent, widely registered in Malaysia for respiratory indications such as bronchitis and chronic obstructive pulmonary disease (COPD). However, the current Evidence Pack contains no TxGNN-predicted new indications, as prediction pipeline data is not yet populated for this candidate. Due to critical data gaps in MOA, safety labelling, and prediction output, this report reflects a preliminary status only and a full repurposing assessment cannot yet be completed.

Quick Overview

Item	Content
Original Indication	Respiratory conditions (mucolytic/expectorant use; detailed NPRA text not populated in this dataset)
Predicted New Indication	Not available — TxGNN predictions not yet generated
TxGNN Prediction Score	Not available
Evidence Level	N/A (no prediction output)
Malaysia Market Status	✓ Marketed
Number of Registrations	20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for this Evidence Pack entry. Based on known pharmacological information, Ambroxol Hydrochloride belongs to the benzylamine class of mucolytics. It is a metabolite of bromhexine and is widely used to reduce mucus viscosity in the airways, facilitating expectoration. Its efficacy in respiratory conditions such as acute and chronic bronchitis, COPD, and asthma-associated secretion disorders has been extensively demonstrated in clinical practice.

Because TxGNN predictions have not yet been generated for this candidate, it is not possible to evaluate mechanistic connections between the original indication and any proposed new indication at this time. Ambroxol has been studied in emerging research areas — including neurological diseases (e.g., Gaucher’s disease, Parkinson’s disease via GBA pathway modulation) and local analgesic effects — however, none of these directions are currently supported by the prediction data in this Evidence Pack.

A complete repurposing rationale analysis should be conducted once TxGNN prediction output and DrugBank MOA data become available.

Clinical Trial Evidence

Currently no related clinical trials registered in this Evidence Pack. TxGNN prediction data required before evidence retrieval can be targeted.

Literature Evidence

Currently no related literature available in this Evidence Pack. TxGNN prediction data required to identify relevant publications.

Malaysia Market Information

This drug holds 20 registrations with Malaysia NPRA and is confirmed as actively marketed. However, individual registration details (authorization numbers, product names, dosage forms, and approved indication text) were not populated in the current dataset.

Item	Status
Malaysia NPRA Registration	✓ Confirmed (20 licences)
Market Status	✓ Marketed
Licence Detail Availability	Not populated in current Evidence Pack

To obtain full licence details, query the Malaysia NPRA product search portal directly using “AMBROXOL HYDROCHLORIDE” as the active ingredient.

Safety Considerations

Please refer to the package insert for safety information.

Note: Both key warnings and contraindications are flagged as Blocking data gaps (DG001) in this Evidence Pack. This prevents completion of a standard S1 safety screen. Retrieval of the NPRA-registered package insert PDF is required before any safety-dependent decision can be made.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction pipeline has not yet produced output for this candidate, and two blocking data gaps (package insert safety data and MOA) prevent meaningful repurposing evaluation. No evidence review, mechanistic analysis, or go/no-go recommendation is possible at this stage.

To proceed, the following is needed:

[Critical — Blocking] Run TxGNN prediction pipeline for Ambroxol Hydrochloride to generate predicted_indications output
[Critical — Blocking] Retrieve and parse the NPRA-registered package insert PDF to populate key warnings and contraindications (DG001)
[High] Query DrugBank API for Ambroxol Hydrochloride to populate drugbank_id, MOA, categories, and toxicity data (DG002)
[Medium] Re-query NPRA with individual licence numbers to populate product names, dosage forms, and approved indication text for the 20 registered products
Once the above are resolved, re-run the Evidence Pack generation (target version v5) and proceed with full S1–S3 evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.